As a pediatric oncologist, I am a member of the multi-disciplinary neuro-oncology team who cares for children with brain and spinal cord tumors. The patient and family are the central members of this team and depending on the unique needs of each child may include a pediatric neuro-radiologist, neurosurgeon, radiation oncologist, social worker, neuro-psychologist, neuro-ophthalmologist and endocrinologist. Our goal is to provide a comprehensive, coordinated plan of care that is based on the best medical evidence available.
We know that while many children are cured of their cancers, there will be some children who are not cured, despite very intense therapy. These children provide the inspiration for the work in my laboratory, which focuses on identifying genes, and hence proteins, that pediatric cancer cells rely upon for growth and survival. Past work has focused on identifying small molecular inhibitors of pediatric embryonal cancers and more recently subsets of malignant gliomas. We hope that by taking this approach in combination with chemotherapy or radiation, we can eventually offer new therapies for children with malignant brain tumors or other aggressive pediatric cancers.
I believe it is a great privilege to be involved in the care of our patient and their families. They deserve kindness and compassion. Together, with the advantages of the multidisciplinary team, Children's Hospital of Philadelphia provides an excellent place for a child to be cared for with a pediatric brain or spinal cord tumor.
MD - University of Maryland School of Medicine, Baltimore, MD
Pediatrics - The Children's Hospital of Philadelphia, Philadelphia, PA
Pediatrics - The Children's Hospital of Philadelphia, Philadelphia, PA
Pediatric Hematology/Oncology - The Children's Hospital of Philadelphia, Philadelphia, PA
PhD - University of Maryland School of Medicine, Baltimore, MD
Associate Professor, Perelman School of Medicine at the University of Pennsylvania
Replicative stress and pediatric cancer
Ijaz H, Koptyra M, Gaonkar KS, Rokita JL, Baubet VP, Tauhid L, Zhu Y, Brown M, Lopez G, Zhang B, Diskin SJ, Vaksman Z, Mason JL, Appert E, Lilly J, Lulla R, De Raedt T, Heath AP, Felmeister A, Raman P, Nazarian J, Santi MR, Storm PB, Resnick A, Waanders AJ, Cole KA; Children’s Brain Tumor Tissue Consortium. Pediatric High Grade Glioma Resources from the Children's Brain Tumor Tissue Consortium (CBTTC). Neuro Oncol 2019 Oct 15. PMID: 31613963
Hart LS, Rader J, Raman P, Batra V, Russell MR, Tsang M, Gagliardi M, Chen L, Martinez D, Li Y, Wood A, Kim S, Parasuraman S, Delach S, Cole KA, Krupa S, Boehm M, Peters M, Caponigro G, Maris JM. Preclinical therapeutic synergy of MEK1/2 and CDK4/6 inhibition in neuroblastoma. Clin Cancer Res. 2017;23(7):1785-1796.
Shah AC, Minturn JE, Li Y, Belasco JB, Phillips PC, Kang TI1, Cole KA, Waanders AJ, Pollack R, Didomenico C, Wildes C, Fisher MJ. Carboplatin Rechallenge After Hypersensitivity Reactions in Pediatric Patients With Low-Grade Glioma. Pediatr Blood Cancer. 2016 Jan;63(1):21-6.
Russell MR, Penikis A, Oldridge DA, Alvarez-Dominguez JR, McDaniel L, Diamond M, Padovan O, Raman P, Li Y, Wei JS, Zhang S, Gnanchandran J, Seeger R, Asgharzadeh S, Khan J, Diskin SJ, Maris JM, Cole KA. CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus. Cancer Res. 2015 Aug 1;75(15):3155-66.
Russell Mike, Penikis Annalise, Oldridge Derek, Alvarez-Dominguez Juan, McDaniel Lee, Diamond Maura, Padovan Olivia, Raman Pichai, Li Yimei, Wei Jun, Gnanachandran Janahan, Zhang Shile, Seeger Robert, Asgharzadeh Shahab, Khan Javed, Diskin Sharon, Maris John, Cole Kristina: CASC15-S is a tumor suppressor lncRNA at the 6p22 neuroblastoma susceptibility locus. Cancer research epub 10.1158/0008-5472, June 2015.
Tamhankar Madhura, Paessler Michele, Kharlip Julia, Shekdar Karuna, Burnham Jon and Cole Kristina : A 16-year-old boy with a suprasellar mass. J Neuroophthalmol 34(3): 295-300, Sept 2014.
de Blank Peter, Cole Kristina, Kersun Leslie, Green Abby, Wilkes Jennifer, Belasco Jean, Bagatell Rochelle, Bailey Leonard, Fisher Michael: fdg-pet in two cases of neurofibromatosis type 1 and atypical malignancies. Curr Oncol. 21(2): e345-e348, Apr 2014.
Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, Li Y, Carpenter EL, Attiyeh EF, Diskin SJ, Kim S, Parasuraman S, Caponigro G, Schnepp RW, Wood AC, Pawel B, Cole KA, Maris JM.: Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 19(22): 6173-82. Nov 2013.
Khanna Anchit, Kauko Otto, Bockelman Camilla, Laine Anni, Schreck Ilona, Partanen Johanna I, Szwajda Agnieszka, Bormann Stefanie, Bilgen Turker, Helenius Merja, Pokharel Yuba R, Pimanda John E, Russel Mike R, Haglund Caj, Cole Kristina A, Klefstrom Juha, Aittokallio Tero, Weiss Carsten, Ristimaki Ari, Visakorpi Tapio, Westermarck Jukka: Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells. Cancer Research 73(22): 6757-69, November 2013 Notes: doi: 10.1158/0008-5472.CAN-13-1002. Epub 2013 Sep 26.
Pugh Trevor J, Morozova Olena, Attiyeh Edward F, Asgharzadeh Shahab, Wei Jun S, Auclair Daniel, Carter Scott L, Cibulskis Kristian, Hanna Megan, Kiezun Adam, Kim Jaegil, Lawrence Michael S, Lichenstein Lee, McKenna Aaron, Pedamallu Chandra Sekhar, Ramos Alex H, Shefler Erica, Sivachenko Andrey, Sougnez Carrie, Stewart Chip, Ally Adrian, Birol Inanc, Chiu Readman, Corbett Richard D, Hirst Martin, Jackman Shaun D, Kamoh Baljit, Khodabakshi Alireza Hadj, Krzywinski Martin, Lo Allan, Moore Richard A, Mungall Karen L, Qian Jenny, Tam Angela, Thiessen Nina, Zhao Yongjun, Cole Kristina A, Diamond Maura, Diskin Sharon J, Mosse Yael P, Wood Andrew C, Ji Lingyun, Sposto Richard, Badgett Thomas, London Wendy B, Moyer Yvonne, Gastier-Foster Julie M, Smith Malcolm A, Auvil Jaime M Guidry, Gerhard Daniela S, Hogarty Michael D, Jones Steven J M, Lander Eric S, Gabriel Stacey B, Getz Gad, Seeger Robert C, Khan Javed, Marra Marco A, Meyerson Matthew, Maris John M: The genetic landscape of high-risk neuroblastoma. Nature Genetics 45(3): 279-84, March 2013 Notes: doi: 10.1038/ng.2529. Epub 2013 Jan 20.
Russell Mike R, Levin Kirill, Rader Julieann, Belcastro Lili, Li Yimei, Martinez Daniel, Pawel Bruce, Shumway Stuart D, Maris John M, Cole Kristina A: Combination therapy targeting the chk1 and wee1 kinases shows therapeutic efficacy in neuroblastoma. Cancer research 73(2): 776-84, Jan 2013.
Cole KA and Cunningham D: Transfusion Medicine and Blood Products. In Comprehensive Pediatric Hospital Medicine, (Zaoutis L, Chiang V, eds.). Mosby Elsevier, 2007.
Russell M, Penikis A, Oldridge D, Alvarez-Dominguez JR, McDaniel L, Diamond M, Padovan O, Raman P, Li Y, Wei J, Zhang S, Gnanachandran J, Seeger R, Asgharzadeh S, Khan J, Diskin S, John Maris JM, Cole K: CASC15 is a tumor suppressor lncRNA at the 6p22 neuroblastoma susceptibility locus. American Association for Cancer Research Annual Meeting, Philadelphia PA. Poster presentation. 2015.
Russell1 MR, Penikis A, Oldridge D, Alvarez-Dominguez JA, McDaniel1 L, Diamond M, Padovan O, Raman P, Wei J, Zhang S, Gnanchandran J, Seeger R, Asgharzadeh S, Khan J, Diskin S, Maris JM and Cole KA: The Long Intergenic Noncoding RNA LINC00340 is a Neuroblastoma Susceptibility Gene. Advances in Neuroblastoma Research Meeting, Cologne Germany. Oral Plenary Presentation. 2014.
Rader J, Hart L, Russell M, Nakazawa M, Belcastro L, Martinez D, Carpenter E, Kim S, Parasuraman S, Caponigro G, Schnepp R, Wood A, Pawel1 B, Watson D, Warren P, Cole K and Maris J : CDK4/CDK6 inhibition is potently active in a definable subset of human neuroblastomas. American Association for Cancer Research Annual Meeting, Washington DC. Poster Presentation. 2013.
"The lncRNA CASC15 is a target of the 6p22 neuroblastoma GWAS susceptibility locus", The International Conference on Non-Coding RNAs, Chania, Crete, Greece, June 2015.
"Translational Genomics in Pediatric Neuroblastoma", Children's Hospital Pittsburgh, Pittsburgh, PA, October 2014.
"Checkpoint inhibitory strategies in MYCN driven pediatric cancers", Institute for Cancer Research, London, UK, February 2013.
2010, Best Abstract and Presentation Award, ANR, Stockholm
2009, AACR-AFLAC Scholar in Training Award, AACR, Denver, CO
2009, The NCI Mentored Clinical Scientist Development Award (K08)
2007, ASCO Young Investigator Award
2007, NCI Institutional Clinical Oncology Research Career Development Award (K12)
2007, Children's Neuroblastoma Cancer Foundation Grant Recipient
2007, Children's Hospital of Philadelphia Fellow Research Day Award
2007, The David G. Nathan Award, Society for Pediatric Research and American Society for Pediatric Hematology Oncology
2007, William Guy Forbeck Scholar Award
2005, Ruth L. Kirschstein Institutional National Research Service Award (T32), University of Pennsylvania Cancer Center
2001, The Virchow Prize for Excellence in Pathology, University of Maryland School of Medicine
1999, AACR-AFLAC Scholar in Cancer Research Award, AACR, Philadelphia, PA
1998, National Institutes of Health Material Transfer Award
1998, Abstract Award, World Congress on Advances in Oncology and International Symposium on Molecular Medicine, Crete, Greece
1997, University of Maryland Graduate School Merit Award
1994, Material Transfer Award for Research Efforts in Pathology, National Cancer Institute, NIH
2010-present, Journal of Clinical Investigation, ad hoc reviewer
2008-present, Genes Chromosomes and Cancer, ad hoc reviewer
2012-present, Institutional Animal Care and Use Committee (IACUC)
2008-present, Pediatric Protocol Review Committee
2005-present, Interviewer for Pediatrics Residency Program
2015-present, Pacific Neuro-Oncology Consortium
2015-present, Society for Neuro-Oncology
2007-present, Children's Oncology Group (National Study Chair, Protocol ADVL1312)
2007-present, American Society of Pediatric Hematology/Oncology
2007-present, American Society of Clinical Oncology
1994-present, American Association for Cancer Research
The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments.
Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care.
The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.